Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma ; volume:10 ; number:1 ; day:15 ; month:4 ; year:2024 ; pages:1-13 ; date:12.2024
Cell death discovery ; 10, Heft 1 (15.4.2024), 1-13, 12.2024
- Urheber
-
Cavallo, Maria R.
Yo, Jacob C.
Gallant, Kayla C.
Cunanan, Camille J.
Amirfallah, Amirali
Daniali, Marzieh
Sanders, Alyssa B.
Aplin, Andrew E.
Pribitkin, Edmund A.
Hartsough, Edward J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41420-024-01945-0
- URN
-
urn:nbn:de:101:1-2406272114298.006565431694
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cavallo, Maria R.
- Yo, Jacob C.
- Gallant, Kayla C.
- Cunanan, Camille J.
- Amirfallah, Amirali
- Daniali, Marzieh
- Sanders, Alyssa B.
- Aplin, Andrew E.
- Pribitkin, Edmund A.
- Hartsough, Edward J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Phospho-proteomic analysis of B-Raf complexes
Mutationsscreening von A-Raf und B-Raf in humanen Glioblastom-Tumorproben
B-Raf specific antibody responses in melanoma patients
B-Raf and the inhibitors: from bench to bedside
MCL.
Functional analysis of the B-raf and raf-1 proto oncogenes in B lymphocytes
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf
BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management
Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation
Phospho-proteomic analysis of B-Raf complexes
Mutationsscreening von A-Raf und B-Raf in humanen Glioblastom-Tumorproben
B-Raf specific antibody responses in melanoma patients
B-Raf and the inhibitors: from bench to bedside
MCL.
Functional analysis of the B-raf and raf-1 proto oncogenes in B lymphocytes
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf
BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management
Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation
Phospho-proteomic analysis of B-Raf complexes
Mutationsscreening von A-Raf und B-Raf in humanen Glioblastom-Tumorproben
B-Raf specific antibody responses in melanoma patients
B-Raf and the inhibitors: from bench to bedside
MCL.
Functional analysis of the B-raf and raf-1 proto oncogenes in B lymphocytes
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf
BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management
Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor